UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
________________
FORM
8-K
________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 10, 2011
LIGAND
PHARMACEUTICALS INCORPORATED
(Exact
Name of Registrant as Specified in Its Charter)
________________
|
Delaware |
001-33093 |
77-0160744 |
|
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
11085 North Torrey Pines Road, Suite 300, La Jolla California, 92037 (Address
of Principal Executive Offices) (Zip Code)
|
(858) 550-7500 |
|
(Registrant’s Telephone Number, Including Area Code) |
|
|
| N/A |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On May 10, 2011, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2011. A copy of this press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits. |
||
|
Exhibit No. |
Description |
||
|
99.1 |
Press release of the Company dated May 10, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has caused this report to be signed on its behalf by the undersigned.
|
LIGAND PHARMACEUTICALS INCORPORATED |
||||
| Date: | May 10, 2011 | By: |
/s/ Charles S. Berkman |
|
|
Name: |
Charles S. Berkman |
|||
|
Title: |
Vice President, General Counsel and Secretary |
|||
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
99.1 |
Press release of the Company dated May 10, 2011. |